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Acellular dermal matrices (ADMs) are broadly utilized 
as an adjunct to prosthetic breast reconstruction. They of-
fer soft-tissue support to maintain the lateral and inframa-
mmary folds and can facilitate a match of the dimensions 
of the periprosthetic lamella with the mastectomy skin 
flap envelope.1,2 ADMs are distinguished from one anoth-
er by their clinical performance, traditionally measured 
by complication rates, and by their cost, a factor that will 
become even more critical with bundled payment mod-
els on the horizon.3–7 The cost of using an ADM not only 
includes its price and impact on expensive reconstructive 
failures but also its potential for limiting the number of 
downstream reconstructive interventions.3,4,8,9 Increased 
Background: Several acellular dermal matrices (ADMs) can be used to provide soft-
tissue support for post- and prepectoral prosthetic breast reconstructions. Yet, several 
recent meta-analysis suggest that due to a lack of rigorous evaluation in the setting of 
head-to-head prospective randomized control trials, few reliable conclusions regarding 
performance outcomes can be drawn. We compare Cortiva 1 mm to AlloDerm RTU in 
the setting of submuscular reconstruction in one study, and prepectoral in the second. 
Moreover, we present the findings from the interim analysis in our submuscular study.
Methods: Using a single-blinded prospective randomized control trial design, we 
compare outcomes in 180 patients undergoing submuscular breast reconstruction 
with 16 × 8 cm ADM support (either Cortiva 1 mm or AlloDerm RTU). A parallel 
study evaluates 16 × 20 cm sheets of these ADMs in 180 patients undergoing prepec-
toral reconstructions. Time to drain removal, complications, fill volumes, patient-
reported outcomes, and narcotic consumption are prospectively evaluated.
Results: Interim analysis of 59 breasts in the submuscular study arm (Cortiva n = 
31; AlloDerm n = 28) revealed no statistically significant differences with respect 
to outcome. At the time of interim analysis, the AlloDerm RTU group contained 
a higher proportion of never-smokers (P = 0.009), while patients implanted with 
Cortiva 1 mm received a larger tissue expander (P = 0.02).
Conclusion: We present a protocol for a robust randomized control trial to evalu-
ate outcomes in both submuscular and prepectoral prosthetic breast reconstruc-
tion assisted by 2 distinct types of ADM. Our interim analysis reveals no evidence 
of inferiority of outcomes in a comparison of AlloDerm to Cortiva. (Plast Recon-
str Surg Glob Open 2018;6:e2013; doi: 10.1097/GOX.0000000000002013; Published 
 online 13 November 2018.)
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initial cost of one product over another may be justifiable 
if it increases overall value-based care by improving out-
comes and/or limiting future procedures.9
Although a large body of evidence exists evaluating the 
safety and complication rates associated with ADM-assist-
ed prosthetic breast reconstruction, there is a surprising 
dearth of high quality (level 1 or level 2 evidence) stud-
ies, including prospective randomized controlled trials 
(RCTs), on the topic. This is a significant limitation that 
diminishes the utility of recent meta-analyses on ADM 
use in prosthetic breast reconstruction and prevents cli-
nicians from effectively interpreting the results of these 
studies without the presence of bias inherent in retrospec-
tive study designs.10–12 The BREAST trial, the first RCT to 
compare ADMs in submuscular breast reconstruction, 
showed that overall complication and implant loss rates 
with freeze-dried AlloDerm were comparable with Der-
maMatrix using a noninferiority design.13–15 A subsequent 
RCT comparing ADM slings in submuscular reconstruc-
tions failed to demonstrate significant differences in out-
comes between AlloDerm RTU and AlloMax. This study, 
however, may have been underpowered as complications 
rates of 8% versus 26.1% were not found to be significant-
ly different.16 To our knowledge, there are no published 
RCTs comparing ADMs to one another when used in pre-
pectoral breast reconstruction, an increasingly popular 
technique for prosthetic reconstruction Given the lack of 
high-quality studies available, a significant need remains 
for carefully designed and adequately powered RCTs com-
paring outcomes between various ADMs in submuscular 
and prepectoral prosthetic breast reconstruction.
Cortiva is a Tutoplast-sterilized human ADM with 
similar vascular, collagen, and elastin remodeling char-
acteristics when compared with AlloDerm on histological 
analyses.17 To date, there are limited studies comparing 
complication rates and outcomes between Cortiva ADM 
and AlloDerm ADM. The only existing studies have dem-
onstrated similar complication rates; however, these are 
limited by their retrospective study design.18–21 In this 
study, we introduce a robust RCT study design to compare 
clinical and patient-reported outcomes between Cortiva 
ADM and AlloDerm RTU ADM when used as a sling to 
support tissue expanders placed in the submuscular loca-
tion in one study arm, and prepectoral reconstructions 
with tissue expanders (TEs) or direct-to-implants (DTI) 
in a separate study arm. Furthermore, we present results 
from our interim analysis of the submuscular study arm.
METHODS
Study Design
We are conducting a prospective, single-blinded, 
randomized control trial comparing AlloDerm RTU 
(Allergan Medical, Irvine, Calif.) medium thickness 
(1.6 ± 0.4 mm) to Cortiva 1 mm (RTI Surgical, Alachua, 
Fla.) Allograft Dermis (1.0 ± 0.2 mm) in the practices of 
TMM and MMT. Patients undergoing submuscular breast 
reconstruction with a TE and 16 × 8 cm ADM sling consist-
ing of either AlloDerm or Cortiva are compared in one 
study arm. Patients undergoing prepectoral breast recon-
struction with either DTI or TE supported by a 20 × 16 cm 
ADM sheet are compared in a separate study arm. In both 
arms, randomized patients are allocated 1:1 to one ADM 
or the other. This study is approved by our institutional 
review board (201606168) and listed on clinicaltrials.gov 
(NCT02891759).
We began enrolling patients for submuscular re-
construction using an ADM sling in February 2017. We 
subsequently noted a significant shift to prepectoral re-
constructions both nationally and in our own practices,22,23 
and added the prepectoral arm to optimize enrollment 
rates and reflect our own pattern of practice. We deter-
mined that the perceived and reported differences be-
tween prepectoral and submuscular reconstructions like 
pain and animation deformity would be too profound,24,25 
and create too much variability to be included in the same 
analysis and so parallel prepectoral and submuscular arms 
were initiated (Fig. 1).
Patient Selection
Female patients, aged 22–70 years old, undergoing im-
mediate prosthetic reconstruction following therapeutic 
or prophylactic skin- or nipple-sparing mastectomy with 
a body mass index (BMI) less than 36 kg/m2 are enrolled. 
We have excluded patients who are pregnant, breastfeed-
ing immediately before mastectomy, unwilling to sign or 
unable to comprehend written informed consent. The 
decision to proceed with prepectoral or submuscular 
reconstruction with either a TE or DTI is determined 
preoperatively. Our consent process, however, maintains 
flexibility to choose the alternative plane for implant 
placement, and device type, if determined clinically ap-
propriate by the plastic surgeon. In those instances, we 
would continue to use the ADM to which the patient was 
randomized (ie, if the patient was told they would most 
likely receive a prepectoral immediate implant and was 
randomized to a 20 × 16 cm AlloDerm RTU preoperatively, 
but was intraoperatively switched to a submuscular TE, 
then the patient would be switched to the submuscular 
study arm and would still receive AlloDerm RTU, but a 
16 × 8 cm sheet instead).
Surgical Procedure for Submuscular Reconstruction with 
Acellular Dermal Matrix Sling
Submuscular reconstructions are performed imme-
diately following a skin- or nipple-sparing mastectomy. 
The pectoralis major muscle is elevated by releasing its 
caudal attachments to create a submuscular pocket that 
accommodates a TE selected based on base width, mas-
tectomy specimen weight, and patient goals. Using ab-
sorbable suture, through transverse incisions, the ADM 
is secured along the medial, lateral, and inframammary 
fold, the TE placed, and the caudal edge of the pectoralis 
sutured to the cephalad leading edge of the ADM. For 
lateral radial incisions, the ADM is secured medially and 
centrally, the TE placed, and ADM inset completed along 
the lateral mammary fold. For inframammary incisions, 
the ADM is secured to the caudal edge of the pectoralis 
and the medial and lateral mammary folds defined be-
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fore the TE is placed and the ADM secured to define the 
inframammary fold.
Surgical Procedure for Prepectoral Reconstructions with 
Acellular Dermal Matrix
The ADM is manually fenestrated and tacked superi-
orly to define the upper pole of the reconstruction after 
which the medial and lateral mammary folds are defined 
by the ADM with absorbable, tacking sutures. DTIs are 
placed if the skin envelopes are deemed adequately per-
fused by clinical judgment occasionally supplemented 
with indocyanine green and laser-assisted imaging. In 
these cases, the ADM is draped over the implant with suf-
ficient tension to minimize the risk of malrotation. Oth-
erwise, a TE is placed, tabbed to avoid malposition, with 
additional lower pole laxity accounted for with the inset. 
The inframammary border of the ADM inset is placed last, 
with a gutter to reinforce the integrity of the lower pole 
when sufficient ADM is available.
Study Endpoints
Patients undergoing TE placement in either study arm 
are followed until exchange with an implant, flap, or both, 
or premature device removal for any reason. Patients un-
dergoing DTI reconstruction are followed for at least 3 
months postoperatively. Patients undergoing reoperation 
of the surgical site without device exchange or removal 
are kept in the study. Breast-level data are independently 
collected for bilateral cases so if one device is removed or 
exchanged prematurely, the patient remains in the study 
until the contralateral breast is removed or exchanged for 
TEs, or at least 3 months postoperatively for DTIs. Date of 
drain removal, which occurs once output drops below 30 
cc for 24 hours, is prospectively recorded.
Outcome Measures
The primary outcome measure, analyzed at the 
breast-level, is premature explantation of the TE be-
fore exchange, or unintended explantation of a DTI 
reconstruction before 3 months. Secondary breast-level 
outcome measures include other complications like se-
roma, cellulitis, wound or ADM dehiscence, or skin flap 
necrosis. We record TE or DTI device size, absolute and 
relative and final TE fill volumes, time to drain removal, 
reason for premature explantation, and the type and 
timing of final reconstruction upon TE exchange. At the 
time of TE removal, the decision to proceed to an im-
plant exchange versus a flap was based on surgeon and 
patient preference with a bias toward flaps in radiated 
patients. ADM integration is semiquantitatively assessed 
at the time of TE exchange or TE or DTI premature re-
moval using a grading scale outlined in Table 5 catego-
rized as 0%, <50%, 50–99%, and 100% ADM integration. 
Patient level data include antibiotic use and narcotic 
consumption postoperatively. Patient-reported outcomes 
are measured with the pre- and postoperative Breast-Q 
Fig. 1. Flowchart for randomized clinical trial study design including study arm, enrollment numbers, 
and outcome metrics.
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for all patients, and Qscore reported as an absolute value 
and ΔQscore for domains where pre- and postoperative 
values are generated.
Sample Size
Sample size determination was based on the primary 
hypothesis test for the incidence of premature TE or DTI 
removal. We assumed a premature TE or DTI removal 
rate of 20% as observed in one ADM group and 9% in the 
other ADM group in patients undergoing prepectoral 
reconstruction and in patients undergoing submuscu-
lar reconstruction, respectively. The hypothesized rates 
are based on published data from our group in >3,000 
breasts who have undergone similar procedures.7,26–28 For 
this phase 2 randomized control trial, we require 180 eli-
gible patients, per arm, to achieve 80% power based on 
the 1-sided Z test with pooled variance to detect a dif-
ference between the incidence rates of the 2 ADMs at a 
0.1 significance level.29 We will separately compare the 
2 ADMs among 180 patients receiving prepectoral and 
among 180 patients receiving submuscular reconstruc-
tion (Fig. 1).
Statistical Analysis
For the final analysis, we will use logistic regression 
models to assess the effect of ADM type accounting for 
other confounding factors like obesity, age, radiation ther-
apy, chemotherapy, lymph node surgery, surgery type, and 
cancer stage on the presence of complications. Variables 
that are significant (P ≤ 0.2) in univariate analysis and/
or clinically relevant will be included in the multivariate 
logistic regression model.
Statistical analysis of Breast-Q data will be performed 
on 18 scales, derived from 6 modules of the Breast-Q for 
breast reconstruction.21 The Breast-Q is scored on a 0–
100 points scale (0-dissatisfied, 100-maximally satisfied) 
using QScore, which has been developed according to 
the Rasch model.30 The Mann-Whitney U test will be used 
to detect the difference in data generated from evalu-
ation of the Breast-Q, TE fills, drain use, and narcotic 
use between ADM types. The Gamma regression in the 
generalized linear model framework will be applied to 
model QScore with incorporation of other confounding 
factors.
Chi-square and the Fisher’s exact test were used in the 
interim analysis to detect the association between ADM 
type and TE or DTI removal incidence and between 
ADM type and complications. For the interim analysis, 
we use descriptive statistics to describe the central ten-
dency and variation of 3 outcome variables—physical 
well-being, satisfaction with information, and satisfac-
tion with plastic surgeon in each arm. Then, we used a 
2-sample t test to compare the mean of each outcome 
between the 2 ADMs. We also used the nonparametric 
Wilcoxon rank-sum statistic to compare the median of 
each outcome between the 2 ADMs. Statistical analy-
ses were performed in SAS (Version 9.4, SAS Institute, 
Cary, N.C.) while descriptive statistics were analyzed and 
graphed in Prism (Version 7.0 for MAC, GraphPad Soft-
ware, La Jolla, Calif.).
RESULTS
Patient Demographics and Surgical Details
Thirty-four patients (Table 1), whose 59 breasts were 
reconstructed with AlloDerm RTU (n = 17 patients, n = 28 
breasts) or Cortiva 1 mm (n = 17 patients, n = 31 breasts) 
submuscular TE, completed the interim analysis (Table 2). 
Nearly half of the reconstructions were for prophylactic 
mastectomy, and there with no statistically significant dif-
ferences with respect to BMI, race, incidence of radiation 
therapy, nipple-sparing mastectomy, bilateral cases, or 
chemotherapy. The AlloDerm RTU group (Table 2) was 
comprised of a significantly higher proportion of patients 
who had never smoked (P = 0.009). Mastectomy specimen 
weight, initial TE fill volume, percentage of the TE initially 
filled, and final TE fill volume was not significantly differ-
ent between groups. The initial size of the TE selected was 
significantly larger in patients reconstructed with Cortiva 
1 mm (P = 0.02).
Drain Removal
In most cases, the 10 French subpectoral drain was 
removed after the 15 French prepectoral drain, with re-
moval of the final drain, regardless of size or location, oc-
curring in 17.7 ± 7.0 days for AlloDerm RTU and 17.0 ± 7.6 
days for Cortiva 1 mm. No significant differences were de-
tected between cohorts (Table 3).
Table 1.  Breast-level Descriptive Statistics of Patients 
Enrolled in the Submuscular Tissue Expander with ADM 
Sling Cohort
Variable AlloDerm RTU Cortiva 1 mm P
N (breasts) 28 31  













Radiation (%) 0.0 3.2 0.62








DCIS, ductal carcinoma in situ.
Table 2. Patient-level Descriptive Statistics of Patients 







N (patients) 17 17 1.0
Breast cancer diagnosis (%) 82.3 94.1 0.30
Age (y) 51.9 ± 12.1 47.5 ± 10.9 0.27








BMI (kg/m2) 26.4 ± 5.2 26.8 ± 3.1 0.76
Smoking status    
 Current smoker 5.8 17.6 0.30
 Never smoker 88.2 47.1 0.009
Bilateral cases (%) 64.7 82.3 0.26
Chemotherapy (%) 23.5 35.3 0.23
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Complications
Complications are presented in Table 4. A clinically de-
tectable seroma was identified in 10.7% (N = 3) of breasts re-
constructed with AlloDerm RTU and 0% with Cortiva 1 mm. 
Premature explantation was performed in no (0.0%) breasts 
reconstructed with AlloDerm RTU and 1 breast (3.2%) re-
constructed with Cortiva 1 mm. The breast associated with 
explantation was also the only one affected by postoperative 
cellulitis, initially treated with oral doxycycline followed by 
intravenous cefazolin before ultimate explantation.
Timing to Second-stage and ADM Integration
Patients underwent planned exchange of TEs for im-
plants or flaps (Table 5) within 145.6 ± 51.6 days in the Allo-
Derm RTU and 167.0 ± 61.5 days in the Cortiva 1 mm cohorts 
(P = 0.27). The majority of patients were exchanged with a 
breast implant alone, but 14.3% in the AlloDerm RTU and 
26.6% in the Cortiva 1 mm groups (P = 0.25) received an 
autologous flap (Table 5). Integration of the ADM to the 
mastectomy flap (Table 5), determined by our semiquanti-
tative analysis, was robust in the majority of patients with no 
significant difference between groups (P = 0.69).
Narcotic Use and Patient-reported Outcomes
Most patients stopped using narcotics for pain control 
within 1 or 2 weeks of the mastectomy with immediate 
 reconstruction (Fig. 2). There were no significant dif-
ferences between the AlloDerm RTU and Cortiva 1 mm 
cohorts with respect to physical well-being, or satisfaction 
with information or plastic surgeon (Table 6).
DISCUSSION
Prosthetic breast reconstruction has benefited from 
the use of ADMs to provide soft-tissue support, maintain 
device position, and limit the manipulation of autolo-
gous tissues. Although abundant data support the use of 
ADMs,31–37 several recent meta-analyses confirm the need 
for additional level 1 and 2 evidence to establish how one 
ADM compares to another and how they are influenced 
by patient and therapeutic factors. There are a limited 
number of randomized control trials specifically compar-
ing one ADM to another when providing support for sub-
muscular reconstructions,13,14,16 and none, in the context 
of prepectoral reconstructions.
The original iteration of this trial excluded prepec-
toral breast reconstructions to minimize technique-  versus 
ADM-associated variability. As our study progressed, how-






N (breasts) 28 31  
Mastectomy specimen weight (g) 676.1 ± 383.6 657.5 ± 237.4 0.15
Tissue expander volume (mL) 496.4 ± 117.0 554.8 ± 76.7 0.02
Initial fill volume (mL) 164.6 ± 125.0 191.3 ± 95.4 0.52
Percentage of tissue expander volume initially filled (%) 32.2 35.6 0.39
Final fill volume (mL) 481.6 ± 186.9 510.0 ± 153.4 0.52
Time to 10 Fr subpectoral drain removal (d) 17.5 ± 7.5 14.7 ± 7.7 0.19
Time to 15 Fr prepectoral drain removal (d) 9.8 ± 4.4 11.5 ± 6.1 0.22
Time to final drain removal 17.7 ± 7.0 17.0 ± 7.6 0.57







N (breasts) 28 31  
Seroma N (breasts) (%) 3 (10.7) 0 (0.0) 0.06
Explantation N (breasts) (%) 0 (0.0) 1 (3.2) 0.35
*There were no explantations due to excess pain or magnetic resonance 
imaging.






N (breasts) 28 31  
Time to second surgery (days) 145.6 ± 51.6 167.0 ± 61.5 0.27
TE exchanged with implant (%) 85.7 73.3 0.25
TE exchanged with flap (%) 14.3 21.4  
TE exchanged with  
flap + implant (%)
0.0 5.2  
Degree of ADM integration* 2.9 ± 0.5 2.8 ± 0.7 0.69
*“0” = 0% integration; “1” = <50% integration; “2” = 51–99% integration; “3” 
= 100% integration.”
Fig. 2. Time to cessation of postoperative narcotics in submuscular 
TEs breast reconstructions with an AlloDerm RTU or Cortiva 1 mm 
sling.







Physical well-being 30.4 ± 12.0 30.5 ± 13.4 0.69
Satisfaction with information 53.1 ± 9.0 49.3 ± 10.0 0.35
Satisfaction with plastic surgeon 46.1 ± 4.9 42.8 ± 7.9 0.22
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ever, we noted a growing percentage of reconstructive 
breast implants in our practice, and nationally, were be-
ing placed prepectoral. Early data on prepectoral recon-
structions suggest that they are associated with less pain,25 
less impact on range of motion,38 higher initial and sub-
sequent rates of TE fill volumes,25 improved aesthetic 
outcomes,23 less capsular contracture following radiother-
apy,39,40 and comparable complication rates to submus-
cular reconstruction.39 That said, the prospective studies 
with long-term follow-up required to further delineate 
the advantages and indications for prepectoral breast re-
constructions are lacking.25,41–43 Therefore, expanding our 
study to specifically evaluate the performance of Cortiva 
versus AlloDerm RTU in prepectoral reconstruction has 
considerable value. Successful and sustainable prepectoral 
reconstruction may be even more reliant on the perfor-
mance of one ADM over another. In addition to providing 
lateral and inframammary fold support, ADMs used for 
prepectoral reconstruction are relied upon to provide up-
per pole coverage, and are typically 2 to 2.5 times larger 
(increasing surface area that needs to incorporate) and 
more expensive.22,23,39 Recognizing the benefit of study-
ing prepectoral reconstructions, but acknowledging the 
marked differences with submuscular reconstructions that 
would preclude inclusion into the same cohort, we have 
added a separate prepectoral study arm comparing Allo-
Derm RTU to Cortiva 1 mm.
We chose a prospective randomized control trial de-
sign to control for population bias, and the numerous 
covariates that impact the heterogeneous population of 
women seeking immediate prosthetic breast reconstruc-
tion. Nonetheless, randomized control trials may possess 
unidentified biases that characterize those patients willing 
to participate in them, and are subject to patients who are 
lost to follow-up. Further, a substantially higher powered 
study would make our findings more robust, and along 
with longer term follow-up would enable us to study the 
impact of these ADMs on capsular contracture rates. Inter-
im analysis of the first 34 patients to complete the submus-
cular arm of our study identified no statistically significant 
findings clearly attributable to the ADM. Moreover, none 
of the postoperative patient-reported outcome metrics 
evaluated differed based on ADM (Table 6). Notably, the 
composition of our study population closely resembled 
that of another RCT, the BREASTrial,13 with some impor-
tant exceptions. The BREASTtrial is skewed to a higher 
proportion of patients with stage III or greater cancers, 
radiation, and chemotherapy than our study (Tables 2 
and 3). Our study, however, is comprised of a high per-
centage of smokers (Table 2), which reflects the general 
population.44 Compared with the BREASTrial, patients in 
our study had drains for a shorter period of time (~17 ver-
sus 21 days), with fewer explantations (0–3.3% versus 5 
to 11.2%). Preliminary data from our RCT also compares 
favorably to retrospective data obtained from Keifer et al.18 
that compares freeze-dried AlloDerm to Cortiva, albeit 
in a more heterogeneous population that included both 
TE and DTI reconstructions. The similar clinical perfor-
mance metrics that we have identified between AlloDerm 
RTU and Cortiva may relate, in part, to similar-appearing 
ADM remodeling on gross examination. We found, us-
ing a semiquantitative assessment, no obvious differences 
in the degree of ADM integration at the time of TE ex-
change (Table 5). Upon histologic examination, Moyer et 
al.17 have also noted similar levels of elastin deposition and 
revascularization of AlloDerm and Cortiva following pros-
thetic breast reconstruction.
CONCLUSIONS
High-quality evidence is needed to compare the per-
formance of various ADMs used in prosthetic breast re-
construction. Prepectoral reconstructions represent a 
unique population within prosthetic breast reconstruc-
tion and have several notable differences when compared 
with submuscular reconstructions. As such, trials com-
paring ADM performance should separate these patient 
cohorts to eliminate the potential bias that plane of pros-
thesis placement can have on outcome. In this study, we 
outline a protocol for a robust RCT to evaluate complica-
tions, clinical outcomes, and patient-reported outcomes 
in both submuscular and prepectoral prosthetic breast 
reconstruction assisted by 2 distinct types of ADM. Interim 
analysis of a limited sample of submuscular reconstruc-
tions reveals no evidence of inferiority of outcomes in a 
comparison of AlloDerm RTU to Cortiva.
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